Direkt zum Inhalt
Merck

SHP-1 Regulates Antigen Cross-Presentation and Is Exploited by Leishmania to Evade Immunity.

Cell reports (2020-12-03)
Sofía C Khouili, Emma C L Cook, Elena Hernández-García, María Martínez-López, Ruth Conde-Garrosa, Salvador Iborra
ZUSAMMENFASSUNG

Intracellular pathogens have evolved strategies to evade detection by cytotoxic CD8+ T lymphocytes (CTLs). Here, we ask whether Leishmania parasites trigger the SHP-1-FcRγ chain inhibitory axis to dampen antigen cross-presentation in dendritic cells expressing the C-type lectin receptor Mincle. We find increased cross-priming of CTLs in Leishmania-infected mice deficient for Mincle or with a selective loss of SHP-1 in CD11c+ cells. The latter also shows improved cross-presentation of cell-associated viral antigens. CTL activation in vitro reveals increased MHC class I-peptide complex expression in Mincle- or SHP-1-deficient CD11c+ cells. Neuraminidase treatment also boosts cross-presentation, suggesting that Leishmania triggers SHP-1-associated sialic-acid-binding receptors. Mechanistically, enhanced antigen processing correlates with reduced endosomal acidification in the absence of SHP-1. Finally, we demonstrate that SHP-1 inhibition improves CD11c+ cell-based vaccination against the parasite. Thus, SHP-1-mediated impairment of cross-presentation can be exploited by pathogens to evade CTLs, and SHP-1 inhibition improves CTL responses during vaccination.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Roche
Neuraminidase (Sialidase), from Arthrobacter ureafaciens
Sigma-Aldrich
SHP1/2 PTPase-Inhibitor, NSC-87877, CAS-Nr. 56932-43-5, Calbiochem, The SHP1/2 PTPase Inhibitor, NSC-87877, also referenced under CAS 56932-43-5, controls the biological activity of SHP1/2 PTPase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.